Alnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease acute hepatic porphyria, with an ultra-high price tag to match.
The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p
The US drugs regulator has tagged F2G’s olorofim as a potential Breakthrough Therapy for life-threatening fungal infections, pledging to expedite development of the mid-stage candidate.
